Investment, Funding & Disinvestments

Developed through a partnership between Masdar City, M42, and Attentive Science, Biosphere Labs aims to address one of the biggest challenges facing researchers and biotechnology companies: access to high-quality laboratory infrastructure.

Antares will lead the research phase and apply its proprietary drug-discovery platform to a limited number of oncology targets before Novartis decides whether to exercise licensing options for individual programmes.

The acquisition is expected to strengthen Merck’s position in the rapidly growing life sciences sector, particularly in areas such as cell and gene therapy, precision diagnostics, multi-omics research, and biopharmaceutical manufacturing.

The strategy aims to enhance national health security, create jobs, promote innovation, and improve access to quality and affordable healthcare commodities while reducing the country’s reliance on imports.

The healthcare package forms part of a broader set of cooperation agreements covering education, green industry, vocational training, and support for small and medium-sized enterprises.

Japan will channel the support through the International Federation of Red Cross and Red Crescent Societies (IFRC), the World Food Programme (WFP), and the United Nations Children’s Fund (UNICEF).

Under the new structure, hospitals and clinics previously operating as NMC Oman will now operate under the Numa Health brand, while EMC will continue as a dedicated sub-brand focused on dermatology and aesthetic medicine.

Under the agreement, Tanmeyah will provide tailored financing solutions for healthcare providers, particularly small and medium-sized facilities that often face constraints in investing in digital infrastructure.

Evaluators examined how the hospital manages patient care across multiple departments, including safety protocols, infection control, medication handling, and continuous quality improvement processes.

The acquisition ranks among AbbVie’s largest transactions in recent years and reflects the company’s strategy to expand its next-generation immunology medicines as competition intensifies across the sector.